MONTREAL, May 24, 2011 /PRNewswire/ - Aptilon Corporation ("Aptilon" or the "Company") (TSX-V: APZ), a leader in onlineaccess to, engagement and interaction with physicians and healthcare professionals on behalf of pharmaceutical and life sciences companies, today announced that its indirect wholly-owned subsidiaries, DMD Marketing LP and DMD Marketing Corp., have
The original note is replaced by a new secured promissory note in the amount of US$21,750,000, being the balance due under the original note as of Aprilá14, 2011. The new note bears interest at the rate of 6.9% per annum and is repayable in increasing monthly installments (ranging from US$226,000 for the first 9 months to US$600,000 for 11 of the last 12 months) from Aprilá15, 2011 until Decemberá15, 2015. It is secured and guaranteed in the same manner as the original note.
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach, message, connect and interact with US physicians and healthcare professionals on the Internet and over mobile devices via multiple access channels. Its innovative service offerings provide targeted impressions and interactions through: video and mobile detailing, ReachNet?áPhysician Access Channel, the DMD database and permission-based email services. Top US pharmaceutical companies and respected healthcare organizations have adopted Aptilon's solutions to market to, engage and interact with leading healthcare practitioners. For more information, visit www.aptilon.com.
ReachNetSM is a service mark of Aptilon Corporation.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aptilon Corporation
Subscribe to our Free Newsletters!
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...